SCHEMBL4925604

SCHEMBL4925604

COCOc1ccc(-n2c(=S)[nH]c3ccc(Cl)cc32)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.50
ALDH1A1 P00352 2/20 0.50
HPGD P15428 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
PSMB8 P28062 1/20 0.49
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
CA12 O43570 3/20 0.40
CA1 P00915 3/20 0.40
CA2 P00918 3/20 0.40
CA9 Q16790 3/20 0.40
HRH3 Q9Y5N1 1/20 0.40
ATM Q13315 1/20 0.40
KCNH2 Q12809 1/20 0.39
THRB P10828 1/20 0.37
ADORA3 P0DMS8 1/20 0.37
ADORA1 P30542 1/20 0.37
GABRP O00591 1/20 0.37
GABRD O14764 1/20 0.37
GABRA1 P14867 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4928559 0.90 PSMB8 (0.47) MAPTALDH1A1HPGDSMN1; SMN2PSMB8
SCHEMBL4928742 0.89 PSMB8 (0.50) MAPTALDH1A1HPGDSMN1; SMN2PSMB8
SCHEMBL4921699 0.87 MAPT (0.66) MAPTALDH1A1HPGDSMN1; SMN2PSMB8
SCHEMBL4928587 0.82 PSMB8 (0.60) MAPTALDH1A1HPGDSMN1; SMN2PSMB8
SCHEMBL4929848 0.79 PSMB8 (0.47) MAPTALDH1A1HPGDSMN1; SMN2PSMB8
SCHEMBL4928555 0.77 ALDH1A1 (0.52) MAPTALDH1A1HPGDSMN1; SMN2PSMB8
SCHEMBL4931051 0.77 PSMB8 (0.57) MAPTALDH1A1HPGDSMN1; SMN2PSMB8
SCHEMBL4930267 0.77 PSMB8 (0.48) MAPTALDH1A1HPGDSMN1; SMN2PSMB8
SCHEMBL4930256 0.76 MAPT (0.66) MAPTALDH1A1HPGDSMN1; SMN2PSMB8
SCHEMBL4930651 0.76 PSMB8 (0.44) MAPTALDH1A1HPGDSMN1; SMN2PSMB8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080021069-A1 Receptor Function Regulating Agent TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-01-24 US disclosed
US-20080021069-A1 Receptor Function Regulating Agent TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-01-24 US disclosed
US-20080021069-A1 Receptor Function Regulating Agent TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-01-24 US disclosed
EP-1810677-A1 RECEPTOR FUNCTION REGULATING AGENT Takeda Pharmaceutical Company Limited (JP) 2007-07-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080021069-A1 Receptor Function Regulating Agent GPR119, INSR, GPR65 MAPT 4574/4885ALDH1A1 1870/4885HPGD 1922/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.